Discovering Brain Cancer Therapies

The Opal team is made up of industry practitioners, academics, scientific advisory board members and a supportive investor group.

The leadership team have the capability to execute hit-lead optimisation programs leading into patent and IND filing with expertise in discovery chemistry, biology and the on-going management of pre-clinical development. Sunil Shah - CEO & Licensing, Andy Morley - CSO, Prashant Shah - Operations & Finance, and Nilesh Dagia - VP Pharmacology & Biology.

The scientific advisory board led by Professor James R. Connor has extensive experience drug discovery, covering academia, biotechnology and pharma covering a broad range of therapeutic classes. The extensive investor group covers a wide range of life science disciplines, technology and finance.